Indicia Expands Ready-To-Use Media Manufacturing with Acquisition

By Dan Stanton

- Last updated on GMT

Related tags Bacteria Microbiology

Indicia Expands Ready-To-Use Media Manufacturing with Acquisition
French CMO Indicia production says the acquisition of Biotechnologie Appliquee will strengthen its ready-to-use media manufacturing and add R&D capabilities to its offerings.

Indicia, a Taden, France based contract manufacturing organization (CMO) which specializes in aseptic filling and manufacture of ready-to-use media for microbiological testing has bought Biotechnologie Appliquee for an undisclosed fee.

President and CEO, Stéphane Legastelois, told that “Indicia Production had no R&D capabilities up to now”​ and this acquisition will add an R&D site to the company as well as a number of new customers.

BA is a small CMO which primarily provides low-volume manufacturing and the deal will, according to Legastelois, expand the flexibility and capacity of Indicia’s manufacturing services.

The company is focused on the production of ready-to-use-media, of which Legastelois said “the market is huge,”​ not just in the pharmaceutical industry but also in cosmetics and food where they are used for "bacterial testing (sterility) of their products."

Ready-to-use-media are used to solve problems in microbiology laboratories where time, equipment and trained personnel are often in short supply, assuring quality for growing different types of cells. QC and validation from a third-party manufacturer saves a company time and money and is thus an increasingly outsourced industry.

”The contract manufacturing market for microbiological testing and aseptic filling is booming," ​said Legastelois. "More industry professionals are now choosing to outsource these services in order to reduce their fixed costs​. They are also showing a keen interest in contract services, which we have just strengthened with this acquisition.”

Indicia currently has no plans to expand its new facility nor add to the four personnel who currently work at Biotechnologie Appliquee.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us